Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Sipp

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Regenerative Medicine|April 1, 2011
Stem cell stratagems in alternative medicineDouglas Sipp
Regenerative Medicine|November 12, 2009
Stem cells and regenerative medicine on the Asian horizon: an economic, industry and social perspectiveDouglas Sipp
Regenerative Medicine|November 9, 2017
Identity and ownership issues in the regulation of autologous cellsDouglas Sipp
International Journal of Hematology|January 20, 2018
Issues in stem cells in Asia and SNAP decisionsDouglas Sipp
Regenerative Medicine|December 6, 2012
Pay-to-participate funding schemes in human cell and tissue clinical studiesDouglas Sipp
Stem Cells Translational Medicine|August 13, 2013
Direct-to-consumer stem cell marketing and regulatory responsesDouglas Sipp
Nature Biotechnology|June 10, 2008
GSK moves on SirtrisDouglas Sipp
Frontiers of Medicine|October 4, 2011
The unregulated commercialization of stem cell treatments: a global perspectiveDouglas Sipp
Neuron|May 26, 2011
Global challenges in stem cell research and the many roads aheadDouglas Sipp
Cell Stem Cell|October 3, 2009
Gold standards in the diamond age: the commodification of pluripotencyDouglas Sipp
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Regenerative Medicine|April 1, 2011
Stem cell stratagems in alternative medicineDouglas Sipp
Regenerative Medicine|November 12, 2009
Stem cells and regenerative medicine on the Asian horizon: an economic, industry and social perspectiveDouglas Sipp
Regenerative Medicine|November 9, 2017
Identity and ownership issues in the regulation of autologous cellsDouglas Sipp
International Journal of Hematology|January 20, 2018
Issues in stem cells in Asia and SNAP decisionsDouglas Sipp
Regenerative Medicine|December 6, 2012
Pay-to-participate funding schemes in human cell and tissue clinical studiesDouglas Sipp
Stem Cells Translational Medicine|August 13, 2013
Direct-to-consumer stem cell marketing and regulatory responsesDouglas Sipp
Nature Biotechnology|June 10, 2008
GSK moves on SirtrisDouglas Sipp
Frontiers of Medicine|October 4, 2011
The unregulated commercialization of stem cell treatments: a global perspectiveDouglas Sipp
Neuron|May 26, 2011
Global challenges in stem cell research and the many roads aheadDouglas Sipp
Cell Stem Cell|October 3, 2009
Gold standards in the diamond age: the commodification of pluripotencyDouglas Sipp
Pageof 6